US Patent

US9303051 — Phosphonate ester derivatives and methods of synthesis thereof

Method of Use · Assigned to Chimerix Inc · Expires 2031-08-31 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of synthesizing phosphonate ester derivatives, including preferred methods for large-scale preparation with high purity.

USPTO Abstract

The disclosure describes methods of synthesis of phosphonate ester derivatives. Preferred methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of phosphonate ester derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of phosphonate ester derivatives.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3165 — Tembexa
U-3165 — Tembexa

Patent Metadata

Patent number
US9303051
Jurisdiction
US
Classification
Method of Use
Expires
2031-08-31
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Chimerix Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.